Diagenode

EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation.


Herviou L, Jourdan M, Martinez AM, Cavalli G, Moreaux J

Plasma cells (PCs) play a major role in the defense of the host organism against pathogens. We have shown that PC generation can be modeled using multi-step culture systems that reproduce the sequential cell differentiation occurring in vivo. Using this unique model, we investigated the role of EZH2 during PC differentiation (PCD) using H3K27me3 and EZH2 ChIP-binding profiles. We then studied the effect of the inhibition of EZH2 enzymatic activity to understand how EZH2 regulates the key functions involved in PCD. EZH2 expression significantly increases in preplasmablasts with H3K27me3 mediated repression of genes involved in B cell and plasma cell identity. EZH2 was also found to be recruited to H3K27me3-free promoters of transcriptionally active genes known to regulate cell proliferation. Inhibition the catalytic activity of EZH2 resulted in B to PC transcriptional changes associated with PC maturation induction, as well as higher immunoglobulin secretion. Altogether, our data suggest that EZH2 is involved in the maintenance of preplasmablast transitory immature proliferative state that supports their amplification.

Tags
Antibody
IPure kit
IP-Star Compact
True MicroChIP kit
iDeal ChIP-seq Kit for Transcription Factors

Share this article

Published
February, 2019

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410195
    H3K27me3 polyclonal antibody - Premium
  • ChIP kit icon
    C01010058
    Auto iDeal ChIP-seq Kit for Transcription Factors
  • ChIP kit icon
    C01010172
    Auto iDeal ChIP-seq Kit for Transcription Factors
  • Kit icon
    C03010010
    Auto IPure kit v2
  • ChIP kit icon
    C01010140
    Auto True MicroChIP kit
  • some alt
    B03000002
    IP-Star® Compact Automated System

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics